Current status of therapy in autoimmune liver disease

Therapeutic Advances in Gastroenterology

Volumn 2, Issue 1, 2009, Pages 11-28

  Hirschfield, Gideon M ^a   Al Harthi, Nadya ^a   Heathcote, E Jenny ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Autoimmune hepatitis; Autoimmune pancreatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis; Secondary sclerosing cholangitis

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; BUDESONIDE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DIHYDRALAZINE; HALOTHANE; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G4; INDOMETACIN; METHOTREXATE; METHYLDOPA; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITROFURANTOIN; PREDNISONE; RAMIPRIL; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TERBINAFINE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; URSODEOXYCHOLIC ACID;

ADRENAL SUPPRESSION; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE PANCREATITIS; BILE DUCT DISEASE; CATARACT; CLINICAL TRIAL; COLITIS; CUSHINGOID SYNDROME; CYTOPENIA; DIABETES MELLITUS; DIARRHEA; FLATULENCE; FLU LIKE SYNDROME; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; LIVER DISEASE; LIVER TOXICITY; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NAUSEA; OSTEOPOROSIS; PANCREATITIS; PNEUMONIA; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; SCLEROSING CHOLANGITIS; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

EID: 77953451735     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X08098966     Document Type: Review

References (165)

1. Abdalian, R., Dhar, P., Jhaveri, K., Haider, M., Guindi, M. and Heathcote, E.J. (2008) Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 47 (3): 949-957.
2. Abdalian, R. and Heathcote, E.J. (2006) Sclerosing cholangitis: a focus on secondary causes. Hepatology 44 (5): 1063-1074.
3. Al-Chalabi, T., Boccato, S., Portmann, B.C., McFarlane, I.G. and Heneghan, M.A. (2006) Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 45 (4): 575-583.
4. Alvarez, F., Berg, P.A., Bianchi, F.B., Bianchi, L., Burroughs, A.K., Cancado, E.L. et al. (1999) International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 (5): 929-938.
5. Angulo, P., Dickson, E.R., Therneau, T.M., Jorgensen, R.A., Smith, C., de Sotel, C.K. et al. (1999) Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 30 (5): 830-835.
6. Angulo, P., Jorgensen, R.A., Keach, J.C., Dickson, E.R., Smith, C. and Lindor, K.D. (2000) Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 31 (2): 318-323.
7. Aqel, B.A., Machicao, V., Rosser, B., Satyanarayana, R., Harnois, D.M. and Dickson, R.C. (2004) Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 38 (9): 805-809.
8. Baggenstoss, A.H., Soloway, R.D., Summerskill, W.H., Elveback, L.R. and Schoenfield, L.J. (1972) Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol 3 (2): 183-198.
9. Bambha, K., Kim, W.R., Talwalkar, J., Torgerson, H., Benson, J.T., Therneau, T.M. et al. (2003) Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 125 (5): 1364-1369.
10. Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Loöoöf, L., Danielsson, A. et al. (2002) Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36 (3): 321-327.
11. Beuers, U., Spengler, U., Kruis, W., Aydemir, U., Wiebecke, B., Heldwein, W. et al. (1992) Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 16 (3): 707-714.
12. Bjornsson, E., Chari, S.T., Smyrk, T.C. and Lindor, K. (2007) Immunoglobulin G 4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology 45 (6): 1547-1554.
13. Bjornsson, E., Olsson, R., Bergquist, A., Lindgren, S., Braden, B., Chapman, R.W. et al. (2008) The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 134 (4): 975-980.
14. Blanco, P.G., Zaman, M.M., Junaidi, O., Sheth, S., Yantiss, R.K., Nasser, I.A. et al. (2004) Induction of colitis in cftr-/- mice results in bile duct injury. Am J Physiol Gastrointest Liver Physiol 287 (2): 491-496.
15. Boner, A.L., Peroni, D., Bodini, A., Delaini, G. and Piacentini, G. (2007) Azithromycin may reduce cholestasis in primary sclerosing cholangitis: a case report and serendipitous observation. Int J Immunopathol Pharmacol 20 (4): 847-849.
16. Buchel, E., van Steenbergen, W., Nevens, F. and Fevery, J. (2002) Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol 97 (12): 3160-3165.
17. Buckles, D.C., Lindor, K.D., Larusso, N.F., Petrovic, L.M. and Gores, G.J. (2002) In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol 97 (5): 1138-1142.
18. Bungay, H.K., Buchel, O.C., Travis, S., Cummings, F. and Chapman, R.W. (2008) Prevalence and determinants of PSC in a cohort of patients with inflammatory bowel disease and normal liver function tests. DDW W 1847 2 (1): 74.
19. Chapman, R.W., Arborgh, B.A., Rhodes, J.M., Summerfield, J.A., Dick, R., Scheuer, P.J. et al. (1980) Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 21 (10): 870-877.
20. Chari, S.T. (2007) Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic's HISORt criteria. J Gastroenterol 42(Suppl 18.): 39-41.
21. Chatur, N., Ramji, A., Bain, V.G., Ma, M.M., Marotta, P.J., Ghent, C.N. et al. (2005) Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 25 (4): 723-727.
22. Chazouillères, O., Poupon, R., Capron, J.P., Metman, E.H., Dhumeaux, D., Amouretti, M. et al. (1990) Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 11 (1): 120-123.
23. Chazouilleres, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O. and Poupon, R. (1998) Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 28 (2): 296-301.
24. Church, N.I., Pereira, S.P., Deheragoda, M.G., Sandanayake, N., Amin, Z., Lees, W.R. et al. (2007) Autoimmune pancreatitis: clinical and radiological features and objective response to steroid therapy in a UK series. Am J Gastroenterol 102 (11): 2417-2425.
25. Church, N.I. and Webster, G.J. (2008) Autoimmune pancreatitis: optimal therapy has not been determined. Am J Gastroenterol 103 (7): 1834-1835.
26. Combes, B., Emerson, S.S., Flye, N.L., Munoz, S.J., Luketic, V.A., Mayo, M.J. et al. (2005) Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 42 (5): 1184-1193.
27. Cook, G.C., Mulligan, R. and Sherlock, S. (1971) Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 40 (158): 159-185.
28. Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C. et al. (2008) Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48 (3): 871-877.
29. Corpechot, C., Carrat, F., Bahr, A., Chretien, Y., Poupon, R.E. and Poupon, R. (2005) The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 128 (2): 297-303.
30. Corpechot, C., Carrat, F., Bonnand, A.M., Poupon, R.E. and Poupon, R. (2000) The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 32 (6): 1196-1199.
31. Corpechot, C., Carrat, F., Poupon, R. and Poupon, R.E. (2002) Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 122 (3): 652-658.
32. Corpechot, C., Poujol-Robert, A., Wendum, D., Galotte, M., Chrétien, Y., Poupon, R.E. et al. (2004) Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Liver Int 24 (3): 187-193.
33. Crowe, J., Christensen, E., Smith, M., Cochrane, M., Ranek, L., Watkinson, G. et al. (1980) Azathioprine in primary biliary cirrhosis: a preliminary report of an international trial. Gastroenterology 78(5Pt1): 1005-1010.
34. Cuarterolo, M., Ciocca, M., Velasco, C.C., Ramonet, M., Gonzàlez, T., Lopez, S. et al. (2006) Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 43 (5): 635-639.
35. Cullen, S.N., Rust, C., Fleming, K., Edwards, C., Beuers, U. and Chapman, R.W. (2008) High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 48 (5): 792-800.
36. Czaja, A.J. (1998) Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 28 (2): 360-365.
37. Czaja, A.J. (2008) Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 7 (3): 319-333.
38. Czaja, A.J. and Carpenter, H.A. (2004) Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 39 (6): 1631-1638.
39. Czaja, A.J. and Carpenter, H.A. (2005) Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 39 (9): 819-825.
40. Czaja, A.J. and Carpenter, H.A. (2006) Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 43 (3): 532-538.
41. Czaja, A.J., Davis, G.L., Ludwig, J., Baggenstoss, A.H. and Taswell, H.F. (1983) Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 85 (3): 713-717.
42. Czaja, A.J., Davis, G.L., Ludwig, J. and Taswell, H.F. (1984) Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 4 (4): 622-627.
43. Czaja, A.J. and Freese, D.K. (2002) Diagnosis and treatment of autoimmune hepatitis. Hepatology 36 (2): 479-497.
44. Czaja, A.J. and Lindor, K.D. (2000) Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 119 (5): 1312-1316.
45. D'Souza, R., Sinnott, P., Glynn, M.J., Sabin, C.A. and Foster, G.R. (2005) An unusual form of autoimmune hepatitis in young Somalian men. Liver Int 25 (2): 325-330.
46. Danielsson, A. and Prytz, H. (1994) Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 8 (6): 585-590.
47. Davies, Y.K., Cox, K.M., Abdullah, B.A., Safta, A., Terry, A.B. and Cox, K.L. (2008) Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 47 (1): 61-67.
48. de Groote, J., Fevery, J. and Lepoutre, L. (1978) Long-term follow-up of chronic active hepatitis of moderate severity. Gut 19 (6): 510-513.
49. Devlin, S.M., Swain, M.G., Urbanski, S.J. and Burak, K.W. (2004) Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 18 (5): 321-326.
50. Dufour, J.F., de Lellis, R. and Kaplan, M.M. (1997) Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 127 (11): 981-985.
51. Faörkkilaö, M., Karvonen, A.L., Nurmi, H., Nuutinen, H., Taavitsainen, M., Pikkarainen, P. et al. (2004) Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 40 (6): 1379-1386.
52. Feld, J.J., Dinh, H., Arenovich, T., Marcus, V.A., Wanless, I.R. and Heathcote, E.J. (2005) Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 42 (1): 53-62.
53. Fickert, P., Wagner, M., Marschall, H.U., Fuchsbichler, A., Zollner, G., Tsybrovskyy, O. et al. (2006) 24-nor Ursodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr 2 (Abcb4) knockout mice. Gastroenterology 130 (2): 465-481.
54. Gardner, T.B. and Chari, S.T. (2008) Autoimmune pancreatitis. Gastroenterol Clin North Am 37 (2): 439-460 vii.
55. Gershwin, M.E. and Mackay, I.R. (2008) The causes of primary biliary cirrhosis: Convenient and inconvenient truths. Hepatology 47 (2): 737-745.
56. Ghazale, A. and Chari, S.T. (2007) Optimising corticosteroid treatment for autoimmune pancreatitis. Gut 56 (12): 1650-1652.
57. Ghazale, A., Chari, S.T., Zhang, L., Smyrk, T.C., Takahashi, N., Levy, M.J. et al. (2008) Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 134 (3): 706-715.
58. Gong, Y., Huang, Z.B., Christensen, E. and Gluud, C. (2008) Ursodeoxycholic acid for primary biliary cirrhosis, Cochrane Database Syst Rev no. 3: CD000551.
59. Goulis, J., Leandro, G. and Burroughs, A.K. (1999) Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 354 (9184): 1053-1060.
60. Gregorio, G.V., Portmann, B., Karani, J., Harrison, P., Donaldson, P.T., Vergani, D. et al. (2001) Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 33 (3): 544-553.
61. Hamano, H., Arakura, N., Muraki, T., Ozaki, Y., Kiyosawa, K. and Kawa, S. (2006) Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis. J Gastroenterol 41 (12): 1197-1205.
62. Hamano, H., Kawa, S., Horiuchi, A., Unno, H., Furuya, N., Akamatsu, T. et al. (2001) High serum IgG 4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 344 (10): 732-738.
63. Harnois, D.M., Angulo, P., Jorgensen, R.A., Larusso, N.F. and Lindor, K.D. (2001) High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 96 (5): 1558-1562.
64. Hayashi, H., Higuchi, T., Ichimiya, H., Hishida, N. and Sakamoto, N. (1990) Asymptomatic primary sclerosing cholangitis treated with ursodeoxycholic acid. Gastroenterology 99 (2): 533-535.
65. Heathcote, E.J., Cauch-Dudek, K., Walker, V., Bailey, R.J., Blendis, L.M., Ghent, C.N. et al. (1994) The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19 (5): 1149-1156.
66. Heathcote, J., Ross, A. and Sherlock, S. (1976) A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology 70(5 Pt 1): 656-660.
67. Hegarty, J.E., Nouri Aria, K.T., Portmann, B., Eddleston, A.L. and Williams, R. (1983) Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 3 (5): 685-689.
68. Hempfling, W., Grunhage, F., Dilger, K., Reichel, C., Beuers, U. and Sauerbruch, T. (2003) Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 38 (1): 196-202.
69. Hendrickse, M.T., Rigney, E., Giaffer, M.H., Soomro, I., Triger, D.R., Underwood, J.C. et al. (1999) Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 117 (2): 400-407.
70. Heneghan, M.A., Norris, S.M., O'Grady, J.G., Harrison, P.M. and McFarlane, I.G. (2001) Management and outcome of pregnancy in autoimmune hepatitis. Gut 48 (1): 97-102.
71. Hennes, E.M., Zeniya, M., Czaja, A.J., Parés, A., Dalekos, G.N., Krawitt, E.L. et al. (2008) Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48 (1): 169-176.
72. Hirano, K., Tada, M., Isayama, H., Yagioka, H., Sasaki, T., Kogure, H. et al. (2007) Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut 56 (12): 1719-1724.
73. Hirschfield, G.M., Kumagi, T. and Heathcote, E.J. (2008) Preventative Hepatology: minimising symptoms and optimising care. Liver Int 28 (7): 922-934.
74. Hommes, D.W. et al. (2008) A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol 42 (5): 522-526.
75. Ichai, P., Duclos-Vallée, J.C., Guettier, C., Hamida, S.B., Antonini, T., Delvart, V. et al. (2007) Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 13 (7): 996-1003.
76. Iwasaki, S., Ohira, H., Nishiguchi, S., Zeniya, M., Kaneko, S., Onji, M. et al. (2008) The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol Res 38 (6): 557-564.
77. Jackson, H., Solaymani-Dodaran, M., Card, T.R., Aithal, G.P., Logan, R. and West, J. (2007) Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology 46 (4): 1131-1137.
78. Johnson, P.J., McFarlane, I.G. and Williams, R. (1995) Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 333 (15): 958-963.
79. Jorgensen, R., Angulo, P., Dickson, E.R. and Lindor, K.D. (2002) Results of long-term ursodiol treatment for patients with primary biliary cirrhosis. Am J Gastroenterol 97 (10): 2647-2650.
80. Kamisawa, T. and Okamoto, A. (2008) IgG4-related sclerosing disease. World J Gastroenterol 14 (25): 3948-3955.
81. Kanzler, S., Gerken, G., Lohr, H., Galle, P.R., Meyer zum Buschenfelde, K.H. and Lohse, A.W. (2001) Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 34 (2): 354-355.
82. Kaplan, M.M., Cheng, S., Price, L.L. and Bonis, P.A. (2004) A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology 39 (4): 915-923.
83. Kaplan, M.M., Schmid, C., Provenzale, D., Sharma, A., Dickstein, G. and McKusick, A. (1999) A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. Gastroenterology 117 (5): 1173-1180.
84. Kaya, M., Petersen, B.T., Angulo, P., Baron, T.H., Andrews, J.C., Gostout, C.J. et al. (2001) Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 96 (4): 1059-1066.
85. Kim, W.R., Therneau, T.M., Wiesner, R.H., Poterucha, J.J., Benson, J.T., Malinchoc, M. et al. (2000) A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 75 (7): 688-694.
86. Kogan, J., Safadi, R., Ashur, Y., Shouval, D. and Ilan, Y. (2002) Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 35 (1): 75-81.
87. Krawitt, E.L. (2006) Autoimmune hepatitis. N Engl J Med 354 (1): 54-66.
88. Kumagi, T., Alswat, K., Hirschfield, G.M. and Heathcote, J. (2008) New insights into autoimmune liver diseases, Hepatol Res 38 (8): 745-61.
89. Kumagi, T. and Heathcote, E.J. (2008) Primary biliary cirrhosis. Orphanet J Rare Dis 3: 1.
90. Larsen, F.S., Vainer, B., Eefsen, M., Bjerring, P.N. and Adel Hansen, B. (2007) Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 13 (23): 3232-3236.
91. La Russo, N.F., Shneider, B.L., Black, D., Gores, G.J., James, S.P., Doo, E. et al. (2006) Primary sclerosing cholangitis: summary of a workshop. Hepatology 44 (3): 746-764.
92. Lee, J., Belanger, A., Doucette, J.T., Stanca, C., Friedman, S. and Bach, N. (2007) Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 5 (11): 1313-1315.
93. Leung, P.S., Rossaro, L., Davis, P.A., Park, O., Tanaka, A., Kikuchi, K. et al. (2007) Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology 46 (5): 1436-1442.
94. Leuschner, M., Maier, K.P., Schlichting, J., Strahl, S., Herrmann, G., Dahm, H.H. et al. (1999) Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 117 (4): 918-925.
95. Lim, K.N., Casanova, R.L., Boyer, T.D. and Bruno, C.J. (2001) Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol 96 (12): 3390-3394.
96. Lindor, K. (2007) Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med 357 (15): 1524-1529.
97. Lindor, K.D. (1997) Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 336 (10): 691-695.
98. Lindor, K.D., Dickson, E.R., Baldus, W.P., Jorgensen, R.A., Ludwig, J., Murtaugh, P.A. et al. (1994) Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 106 (5): 1284-1290.
99. Lindor, K.D., Jorgensen, R.A., Therneau, T.M., Malinchoc, M. and Dickson, E.R. (1997) Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 72 (12): 1137-1140.
100. Lindor, K.D., Therneau, T.M., Jorgensen, R.A., Malinchoc, M. and Dickson, E.R. (1996) Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 110 (5): 1515-1518.
101. Liu, Z.X. and Kaplowitz, N. (2002) Immune-mediated drug-induced liver disease. Clin Liver Dis 6 (3): 755-774.
102. Locke, G.R. 3rd, Therneau, T.M., Ludwig, J., Dickson, E.R. and Lindor, K.D. (1996) Time course of histological progression in primary biliary cirrhosis. Hepatology 23 (1): 52-56.
103. Lok, A.S., Ghany, M.G. and Gerber, M.A. (1994) A young woman with cirrhosis: autoimmune hepatitis vs. alpha 1-antitrypsin deficiency. Hepatology 19 (5): 1302-1306.
104. Lombard, M., Portmann, B., Neuberger, J., Williams, R., Tygstrup, N., Ranek, L. et al. (1993) Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 104 (2): 519-526.
105. Mackay, I.R. (2007) Autoimmune diseases of the liver, autoimmune hepatitis and primary biliary cirrhosis: Unfinished business. Hepatol Res 37(Suppl. 3): S357-S364
106. Makino, I. and Tanaka, H. (1998) From a choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament. J Gastroenterol Hepatol 13 (6): 659-664.
107. Manns, M.P. and Vogel, A. (2006) Autoimmune hepatitis, from mechanisms to therapy. Hepatology 43(2 Suppl. 1): S132-S144
108. Mason, A.L., Farr, G.H., Xu, L., Hubscher, S.G. and Neuberger, J.M. (2004) Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol 99 (12): 2348-2355.
109. Mason, A.L., Lindor, K.D., Bacon, B.R., Vincent, C., Neuberger, J.M. and Wasilenko, S.T. (2008) Clinical Trial: Randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol, Aliment Pharmacol Ther. DOI: 10.1111/j.1365-2036.2008.03799.x.
110. Meagher, S., Yusoff, I., Kennedy, W., Martel, M., Adam, V. and Barkun, A. (2007) The roles of magnetic resonance and endoscopic retrograde cholangiopancreatography (MRCP and ERCP) in the diagnosis of patients with suspected sclerosing cholangitis: a cost-effectiveness analysis. Endoscopy 39 (3): 222-228.
111. Mendes, F.D., Jorgensen, R., Keach, J., Katzmann, J.A., Smyrk, T., Donlinger, J. et al. (2006) Elevated serum IgG 4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 101 (9): 2070-2075.
112. Mendes, F.D., Kim, W.R., Pedersen, R., Therneau, T. and Lindor, K.D. (2008) Mortality attributable to cholestatic liver disease in the United States. Hepatology 47 (4): 1241-1247.
113. Milkiewicz, P., Saksena, S., Hubscher, S.G. and Elias, E. (2000) Wilson's disease with superimposed autoimmune features: report of two cases and review. J Gastroenterol Hepatol 15 (5): 570-574.
114. Mitchell, S.A., Bansi, D.S., Hunt, N., von Bergmann, K., Fleming, K.A. and Chapman, R.W. (2001) A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121 (4): 900-907.
115. Mitchison, H.C., Palmer, J.M., Bassendine, M.F., Watson, A.J., Record, C.O. and James, O.F. (1992) A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 15 (3): 336-344.
116. Miyake, Y., Iwasaki, Y., Terada, R., Takagi, S., Okamaoto, R., Ikeda, H. et al. (2005) Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 43 (6): 951-957.
117. Montano-Loza, A.J., Carpenter, H.A. and Czaja, A.J. (2007 a) Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 27 (4): 507-515.
118. Montano-Loza, A.J., Carpenter, H.A. and Czaja, A.J. (2007 b) Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 102 (5): 1005-1012.
119. Montano-Loza, A.J., Carpenter, H.A. and Czaja, A.J. (2007 c) Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 46 (4): 1138-1145.
120. Murray-Lyon, I.M., Stern, R.B. and Williams, R. (1973) Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1 (7806): 735-737.
121. Nakamura, K., Yoneda, M., Yokohama, S., Tamori, K., Sato, Y., Aso, K. et al. (1998) Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 13 (5): 490-495.
122. O'Brien, C., Joshi, S., Feld, J.J., Guindi, M., Dienes, H.P. and Heathcote, E.J. (2008) Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 48 (2): 550-556.
123. Olsson, R., Boberg, K.M., de Muckadell, O.S., Lindgren, S., Hultcrantz, R., Folvik, G. et al. (2005) High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 129 (5): 1464-1472.
124. Pardi, D.S., Loftus Jr, E.V., Kremers, W.K., Keach, J. and Lindor, K.D. (2003) Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124 (4): 889-893.
125. Pares, A., Caballeria, L. and Rodes, J. (2006) Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 130 (3): 715-720.
126. Poupon, R., Chretien, Y., Poupon, R.E., Ballet, F., Calmus, Y. and Darnis, F. (1987) Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1 (8537): 834-836.
127. Poupon, R.E., Balkau, B., Eschwege, E. and Poupon, R. (1991) A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 324 (22): 1548-1554.
128. Poupon, R.E., Bonnand, A.M., Chretien, Y. and Poupon, R. (1999) Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology 29 (6): 1668-1671.
129. Poupon, R.E., Lindor, K.D., Cauch-Dudek, K., Dickson, E.R., Poupon, R. and Heathcote, E.J. (1997) Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 113 (3): 884-890.
130. Poupon, R.E., Lindor, K.D., Pares, A., Chazouilleres, O., Poupon, R. and Heathcote, E.J. (2003) Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 39 (1): 12-16.
131. Poupon, R.E., Poupon, R. and Balkau, B. (1994) Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 330 (19): 1342-1347.
132. Rautiainen, H., Kaörkkaöinen, P., Karvonen, A.L., Nurmi, H., Pikkarainen, P., Nuutinen, H. et al. (2005) Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 41 (4): 747-752.
133. Richardson, P.D., James, P.D. and Ryder, S.D. (2000) Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 33 (3): 371-375.
134. Roberts, S.K., Therneau, T.M. and Czaja, A.J. (1996) Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 110 (3): 848-857.
135. Rost, D., Rudolph, G., Kloeters-Plachky, P. and Stiehl, A. (2004) Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 40 (3): 693-698.
136. Rudolph, G., Kloeters-Plachky, P., Rost, D. and Stiehl, A. (2007) The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol 19 (6): 487-491.
137. Rust, C. and Beuers, U. (2008) Overlap syndromes among autoimmune liver diseases. World J Gastroenterol 14 (21): 3368-3373.
138. Said, K., Glaumann, H. and Bergquist, A. (2008) Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol 48 (4): 598-605.
139. Santos, E.S., Arosemena, L.R., Raez, L.E., O'Brien, C. and Regev, A. (2006) Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int 26 (5): 625-629.
140. Schalm, S.W., Korman, M.G., Summerskill, W.H., Czaja, A.J. and Baggenstoss, A.H. (1977) Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis 22 (11): 973-980.
141. Schramm, C., Herkel, J., Beuers, U., Kanzler, S., Galle, P.R. and Lohse, A.W. (2006) Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 101 (3): 556-560.
142. Schreuder, T.C., Hubscher, S.G. and Neuberger, J. (2008) Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? Transpl Int DOI: 10.1111/j.1432-2277.2008. 00729.x.
143. Shi, J., Wu, C., Lin, Y., Chen, Y.X., Zhu, L. and Xie, W.F. (2006) Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 101 (7): 1529-1538.
144. Siegel, J.L., Jorgensen, R., Angulo, P. and Lindor, K.D. (2003) Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. J Clin Gastroenterol 37 (2): 183-185.
145. Silveira, M.G. and Lindor, K.D. (2008 a) High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. J Hepatol 48 (5): 692-694.
146. Silveira, M.G. and Lindor, K.D. (2008 b) Treatment ofprimary biliary cirrhosis: therapy with choleretic and immunosuppressive agents. Clin Liver Dis 12 (2): 425-43.
147. Soloway, R.D., Summerskill, W.H., Baggenstoss, A.H., Geall, M.G., Gitnick, G.L., Elveback, I.R. et al. (1972) Clinical, biochemical and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 63 (5): 820-833.
148. Stellon, A.J., Hegarty, J.E., Portmann, B. and Williams, R. (1985) Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. Lancet 1 (8430): 668-670.
149. Stellon, A.J., Keating, J.J., Johnson, P.J., McFarlane, I.G. and Williams, R. (1988) Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 8 (4): 781-784.
150. Stiehl, A., Walker, S., Stiehl, L., Rudolph, G., Hofmann, W.J. and Theilmann, L. (1994) Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 20 (1): 57-64.
151. Stojakovic, T., Putz-Bankuti, C., Fauler, G., Scharnagl, H., Wagner, M., Stadlbauer, V. et al. (2007) Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 46 (3): 776-784.
152. Summerskill, W.H., Korman, M.G., Ammon, H.V. and Baggenstoss, A.H. (1975) Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 16 (11): 876-883.
153. ter Borg, P.C., Schalm, S.W., Hansen, B.E. and van Buuren, H.R. (2006) Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 101 (9): 2044-2050.
154. Toosi, M.N. and Heathcote, J. (2004) Pancreatic pseudotumor with sclerosing pancreato-cholangitis: is this a systemic disease? Am J Gastroenterol 99 (2): 377-382.
155. Topazian, M., Witzig, T.E., Smyrk, T.C., Pulido, J.S., Levy, M.J., Kamath, P.S. et al. (2008) Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 6 (3): 364-366.
156. van Buuren, H.R., van Hoogstraten, H.J.E., Terkivatan, T., Schalm, S.W. and Vleggaar, F.P. (2000) High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 33 (4): 543-548.
157. Vera, A., Moledina, S., Gunson, B., Hubscher, S., Mirza, D., Olliff, S. et al. (2002) Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 360 (9349): 1943-1944.
158. Verma, S., Gunuwan, B., Mendler, M., Govindrajan, S. and Redeker, A. (2004) Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 99 (8): 1510-1516.
159. Verma, S., Torbenson, M. and Thuluvath, P.J. (2007) The impact of ethnicity on the natural history of autoimmune hepatitis Hepatology 46 (6): 1828-1835.
160. Weismuller, T.J., Wedemeyer, J., Kubicka, S., Strassburg, C.P. and Manns, M.P. (2008) The challenges in primary sclerosing cholangitis - aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 48(Suppl 1): S38-S57
161. Werner, M., Bjoörnsson, E., Prytz, H., Lindgren, S., Almer, S., Broomé, U. et al. (2007) Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol 42 (8): 986-991.
162. Werner, M., Prytz, H., Ohlsson, B., Almer, S., Bjoörnsson, E., Bergguist, A. et al. (2008) Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: A nationwide study. Scand J Gastroenterol 1-9.
163. Zein, C.O., Angulo, P. and Lindor, K.D. (2003) When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol 1 (2): 89-95.
164. Zolfino, T., Heneghan, M.A., Norris, S., Harrison, P.M., Portmann, B.C. and McFarlane, I.G. (2002) Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 50 (5): 713-717.
165. Zollner, G., Marschall, H.U., Wagner, M. and Trauner, M. (2006) Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm 3 (3): 231-251.